Unknown Manufacturer
Atibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis.
Atibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis.
Atibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis. It acts as a pattern recognition receptor for bacterial cell wall components in gram-positive and negative bacteria. CD14 antibody action stimulates a pro-inflammatory cytokine cascade often associated with inflammation in sepsis. Atibuclimab neutralization of this antibody results in the inhibition of TNF-a, IL-6 and IL-10, dampening systemic inflammatory responses. Atibuclimab also delays the release of sTNFR(1) and IL-1ra.
Investigated for use/treatment in sepsis and septicemia and pneumonia.
